Roy D. Baynes
CIK 1680739 · Chief Medical Officer · last filed 2026-06-16
Roy D. Baynes is a Chief Medical Officer who has filed 68 SEC Form 4 insider transactions across 7 companies since 2016. The most recent filing, for TVTX, was dated Jun 16, 2026. Across all open-market trades the lifetime net is −$11.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $7.0M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$7.00M
7
68
-$11.41M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TVTX | Director | 41,500 | $55.91 | $2.32M | -$3.09M | 13 | 2026-06-16 |
| NRIX | Director | — | $24.15 | — | $0 | 3 | 2026-05-15 |
| NTRA | Director | 18,512 | $252.22 | $4.67M | -$8.32M | 30 | 2026-04-28 |
| EIKN | Chief Medical Officer | — | $9.49 | — | $0 | 1 | 2026-03-04 |
| AARD | Director | — | $6.42 | — | $0 | 1 | 2025-06-13 |
| ATRA | Director | 1,740 | $7.81 | $13.6K | $0 | 5 | 2022-06-27 |
| Travere Therapeutics, Inc. (RTRX) Delisted | Director | 14,000 | — | — | $0 | 5 | 2020-05-19 |
Recent Filings
68 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-16 | TVTX | Mixed | — | -$128.8K | EDGAR |
| 2026-06-12 | TVTX | Notice (144) | −4,500 | -$225.0K | EDGAR |
| 2026-05-21 | TVTX | Grant (A) | +4,000 | $0 | EDGAR |
| 2026-05-15 | NRIX | Grant (A) | — | $0 | EDGAR |
| 2026-05-06 | TVTX | Mixed | — | -$127.7K | EDGAR |
| 2026-05-05 | TVTX | Notice (144) | −4,500 | -$209.9K | EDGAR |
| 2026-05-04 | TVTX | Mixed | — | -$364.6K | EDGAR |
| 2026-05-01 | TVTX | Notice (144) | −9,750 | -$431.1K | EDGAR |
| 2026-04-28 | NTRA | Grant (A) | +83 | $0 | EDGAR |
| 2026-04-16 | TVTX | Mixed | — | -$775.8K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.